PE20120991A1 - Antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal - Google Patents

Antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal

Info

Publication number
PE20120991A1
PE20120991A1 PE2012000347A PE2012000347A PE20120991A1 PE 20120991 A1 PE20120991 A1 PE 20120991A1 PE 2012000347 A PE2012000347 A PE 2012000347A PE 2012000347 A PE2012000347 A PE 2012000347A PE 20120991 A1 PE20120991 A1 PE 20120991A1
Authority
PE
Peru
Prior art keywords
opious
disorders
gastrointestinal tract
receptor antagonist
opiaceous
Prior art date
Application number
PE2012000347A
Other languages
English (en)
Spanish (es)
Inventor
Richard M Woodward
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120991(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of PE20120991A1 publication Critical patent/PE20120991A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2012000347A 2009-09-18 2010-09-17 Antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal PE20120991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18

Publications (1)

Publication Number Publication Date
PE20120991A1 true PE20120991A1 (es) 2012-08-01

Family

ID=43216894

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000347A PE20120991A1 (es) 2009-09-18 2010-09-17 Antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal

Country Status (19)

Country Link
US (1) US20110071163A1 (https=)
EP (1) EP2477627B1 (https=)
JP (1) JP5797655B2 (https=)
KR (1) KR20120092592A (https=)
CN (2) CN102695508A (https=)
AU (1) AU2010295464B2 (https=)
BR (1) BR112012006069A8 (https=)
CA (1) CA2774021A1 (https=)
CL (1) CL2012000676A1 (https=)
CO (1) CO6531453A2 (https=)
HK (1) HK1210959A1 (https=)
IL (1) IL218679A0 (https=)
MX (1) MX342548B (https=)
NZ (1) NZ598783A (https=)
PE (1) PE20120991A1 (https=)
RU (1) RU2561873C2 (https=)
TW (1) TW201118084A (https=)
WO (1) WO2011035142A1 (https=)
ZA (1) ZA201201954B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2760880B1 (en) 2012-12-28 2015-07-08 Instytut Medycyny Doswiadczalnej I Klinicznej Peptidomimetics and their application
AR108535A1 (es) 2016-05-20 2018-08-29 Esteve Labor Dr Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法
CA3124115A1 (en) 2019-01-04 2020-07-09 Aether Therapeutics Inc. Method for treating drug or alcohol dependency

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ES2188657T3 (es) 1994-04-22 2003-07-01 Yamanouchi Pharma Co Ltd Sistema para la liberacion especifica en el colon de un farmaco.
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
RU2695274C3 (ru) * 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
ES2226933T3 (es) * 1999-11-01 2005-04-01 John Rhodes Composicion para tratar el estreñimiento y el sindrome del intestino irritable.
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
EP1727788B1 (en) * 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) * 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
CA2637274C (en) * 2006-01-24 2013-06-04 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
ES2402749T3 (es) * 2007-12-11 2013-05-08 Theravance, Inc. Derivados de 3-carboxipropil-aminotetralina como antagonistas del receptor de opioide mu
TWI449685B (zh) * 2008-12-10 2014-08-21 Theravance Inc ３－羧基丙基－胺基四氫化萘化合物之結晶型
US9119848B2 (en) * 2009-12-04 2015-09-01 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose

Also Published As

Publication number Publication date
JP5797655B2 (ja) 2015-10-21
ZA201201954B (en) 2012-11-28
NZ598783A (en) 2013-07-26
BR112012006069A2 (pt) 2016-03-29
IL218679A0 (en) 2012-05-31
CO6531453A2 (es) 2012-09-28
RU2012115450A (ru) 2013-10-27
CL2012000676A1 (es) 2012-10-19
RU2561873C2 (ru) 2015-09-10
MX342548B (es) 2016-10-04
KR20120092592A (ko) 2012-08-21
AU2010295464A1 (en) 2012-04-12
CA2774021A1 (en) 2011-03-24
CN104958298A (zh) 2015-10-07
TW201118084A (en) 2011-06-01
MX2012003310A (es) 2012-07-17
EP2477627A1 (en) 2012-07-25
CN102695508A (zh) 2012-09-26
EP2477627B1 (en) 2018-08-15
JP2013505260A (ja) 2013-02-14
HK1210959A1 (en) 2016-05-13
AU2010295464B2 (en) 2015-11-26
US20110071163A1 (en) 2011-03-24
BR112012006069A8 (pt) 2017-10-10
WO2011035142A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
EA200900878A1 (ru) Пиперидиновые агонисты gpcr
EA200900879A1 (ru) Пиперидиновые агонисты gpcr
EA200900796A1 (ru) Пиперидиновые агонисты gpcr
EA200900880A1 (ru) Пиперидиновые агонисты gpcr
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
ECSP12011606A (es) Agonistas de gpr119
GB0812642D0 (en) Compounds
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
EA201200019A1 (ru) Соединения, которые селективно модулируют рецептор св2
EA201291476A1 (ru) Комбинации, содержащие атипичные антипсихотические средства и агонисты taar1
EA201591391A1 (ru) Производное 2-ациламинотиазола или его соль
EA201270428A1 (ru) Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
PE20120991A1 (es) Antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal
WO2011151436A3 (en) Azepin-derivatives as derivatives as g- protein coupled receptor (gpr43) agonists

Legal Events

Date Code Title Description
FC Refusal